Lancashire and South Cumbria
Formulary
 
back
10 Musculoskeletal and joint diseases

This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/

10-01 Drugs used in rheumatic diseases and gout

Belimumab Benlysta®
Formulary

Concentrate for solution for infusion 120mg, 400mg

Black RAG for NICE TA806: TA806 Belimumab for treating lupus nephritis (terminated appraisal) 

Link  MHRA: Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials
Link  NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Link  NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)

Red View adult BNF  View SPC online  View childrens BNF  HCD